2026-01-13 Written by DengyueMed
Tenofovir Amibufenamide (Hengmu®) is a next-generation tenofovir prodrug independently developed in China for the treatment of chronic hepatitis B (CHB). Designed with optimized molecular structure and enhanced liver targeting, Tenofovir Amibufenamide delivers potent antiviral efficacy at a significantly lower dose, while offering a favorable long-term...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
